Pertinax Pharma was founded in 2015 to commercialise the technology we now call Pertinax. Originally developed in the research group of Dr Michele Barbour at the University of Bristol, Pertinax technology is now exclusively produced and marketed by Pertinax Pharma Ltd.
Dr Michele Barbour, Chief Executive Officer has overall responsibility for strategic direction of the company. She is the inventor of Pertinax technology and is also a respected academic in the field of biomaterials and has published over 50 peer-reviewed publications in the field.
As well as her role in Pertinax, Michele is Reader in Biomaterials at the University of Bristol where she leads a research group, teaches undergraduate students and serves as Deputy Head of Bristol Dental School.
Stuart Gibson, Chief Financial Officer is an experienced CFO who since 2001 has focused on early stage biotech and technology companies. During his career he has been involved in a significant number of corporate finance and M&A transactions, an IPO and a wide range of international commercial deals.
Dr Chris Nicklin, Technical Operations Consultant. Drawing on over 25 years’ experience in the Pharmaceutical and Fine Chemical sectors Chris provides technical and operations support for Pertinax. He works with multiple early stage biotech companies engaged in chemical development, scale-up, technology transfer and manufacturing.
Paul Williams, Business Development Manager is an experienced international business development manager with a track record of delivering year-on-year revenue and margin growth through direct and indirect sales channels, particularly in wound care. He joined Pertinax in December 2017 to advance the company’s commercial discussions.
Research and Development Team. The management team are supported by a team of dynamic and versatile scientists who manufacture, characterise, analyse and carry out proof of concept studies illustrating the use of Pertinax in various materials and devices. Our labs permit a range of chemical, physical and biological analysis to be carried out efficiently in house, and we sometimes carry out such analysis under contract for customers and partners.
The company is funded by a combination of equity-based investment and public grant money. If you are or represent an investor and are interested in learning more about investment opportunities, contact us.